← Leaderboards
James S Goydos
Univ Of Med/Dent Nj-R W Johnson Med Sch
$5,196,650
Attributed
$5,382,069
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2007–16$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$5,382,069 · 6
By mechanism
R01$3,542,766 · 2
R21$1,261,618 · 3
K24$577,685 · 1
Top collaborators
- Suzie Chen2 shared
Most similar at Univ Of Med/Dent Nj-R W Johnson Med Sch
Same institution · by research overlap
- Robert S. Dipaola$4,788,194
- David J Foran$10,512,858
- Suzie Chen$3,617,728
- William N Hait$3,322,304
- Joseph Aisner$2,368,234
Others in their field
Top investigators on “Ectopic Expression”
- Mortimer Poncz · University Of Pennsylvania$16,429,447
- Rulang Jiang · University Of Rochester$12,374,347
- Sanjay Ram · Univ Of Massachusetts Med Sch Worcester$12,088,111
- Harvey R. Herschman · University Of California Los Angeles$11,030,586
- Harvey F Lodish · Children'S Hospital Boston$10,609,674
- Jouni Uitto · Thomas Jefferson University$10,553,235
Research focus
Ectopic ExpressionPathogenesisMelanomaMelanocyteReceptorGlutamatesAffectTumorPathway InteractionsMelanoma CellLesionMap Kinase GeneCell LineClinical TrialsFutureGrowthSignal PathwayIn VitroSamplingMetabotropic Glutamate Receptor Type 1ApoptosisIn VivoSignal TransductionCells
Grant awards (28)
Regulation of tumor released exosomes and glutamatergic signaling$168,563
R21 · FY2016 · CA
Regulation of tumor released exosomes and glutamatergic signaling$202,275
R21 · FY2015 · CA
Combination Therapy that Targets Glutamate Signaling in Melanoma$310,426
R01 · FY2014 · CA · contact PI
A Patient Oriented Research Program for Surgical Oncologists$113,392
K24 · FY2014 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$156,814
R01 · FY2013 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$141,295
R01 · FY2013 · CA · contact PI
A Patient Oriented Research Program for Surgical Oncologists$114,822
K24 · FY2013 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$41,168
R01 · FY2013 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$21,676
R01 · FY2013 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$313,989
R01 · FY2012 · CA · contact PI
A Patient Oriented Research Program for Surgical Oncologists$116,209
K24 · FY2012 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$64,515
R01 · FY2012 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$313,989
R01 · FY2011 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$286,624
R01 · FY2011 · CA · contact PI
A Patient Oriented Research Program for Surgical Oncologists$117,557
K24 · FY2011 · CA · contact PI
A Phase II Trial of Riluzole in Patients with Advanced Melanoma$343,200
R21 · FY2010 · CA · contact PI
Combination Therapy that Targets Glutamate Signaling in Melanoma$323,700
R01 · FY2010 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$295,488
R01 · FY2010 · CA · contact PI
A Patient Oriented Research Program for Surgical Oncologists$115,705
K24 · FY2010 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$59,364
R01 · FY2010 · CA · contact PI
A Phase II Trial of Riluzole in Patients with Advanced Melanoma$343,200
R21 · FY2009 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$295,488
R01 · FY2009 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$199,282
R01 · FY2009 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$58,894
R01 · FY2009 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$295,488
R01 · FY2008 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$58,438
R01 · FY2008 · CA · contact PI
Validation of Grm1 as a Therapeutic Target in Melanoma$306,128
R01 · FY2007 · CA · contact PI
A Phase 0 Trial of Riluzole in Patients with Resectable Stage III or IV Melanoma$204,380
R21 · FY2007 · CA · contact PI